Ofatumumab for Post-Transplant Lymphoproliferative Disorder.
Publication/Presentation Date
3-1-2022
Abstract
Posttransplant lymphoproliferative disorder (PTLD) includes a range of abnormal lymphoid proliferation following solid organ or allogeneic hematopoietic stem cell transplantation (HSCT), often associated with Epstein-Barr virus (EBV) infection. Treatment generally incudes rituximab, a chimeric monoclonal antibody directed against CD20. Here we present a 56-year-old woman with EBV-associated PTLD following allogeneic HSCT who was intolerant of rituximab. The patient was instead treated with ofatumumab, a fully human monoclonal antibody directed against CD20, with significant response in EBV viral load and lymphadenopathy. Ofatumumab could represent an important treatment option for patients unable to tolerate rituximab.
Volume
15
Issue
1
First Page
68
Last Page
73
ISSN
2589-0646
Published In/Presented At
Seshadri, M., Crane, G. M., & Gergis, U. (2022). Ofatumumab for Post-Transplant Lymphoproliferative Disorder. Hematology/oncology and stem cell therapy, 15(1), 68–73. https://doi.org/10.1016/j.hemonc.2020.04.004
Disciplines
Medicine and Health Sciences
PubMedID
32413419
Department(s)
Department of Medicine, Lehigh Valley Topper Cancer Institute
Document Type
Article